Key Highlights
- Pfizer shares closed up 1.52% at $25.41, after second-quarter results beat both revenue and earnings estimates.
- Second-quarter revenue reached $15 billion, up 1% operationally, beating the $14.4 billion consensus by 4.41%.
- Adjusted EPS of $0.77 beat the $0.68 estimate by 13.24%, with growth driven by an 18% operational increase in launched and acquired products.
- Pfizer raised full-year 2026 revenue guidance to $60.5 billion to $62.5 billion and reaffirmed adjusted EPS guidance of $2.80 to $3.00.
- CFO Dave Denton is departing, with Cecile Zhigang stepping in as interim CFO.
What Drove the Close
Pfizer (NYSE:PFE) shares closed up 1.52% at $25.41, with a day range of $24.70 to $25.64 on volume of 55.42 million shares, after the company reported second-quarter results that beat Wall Street expectations on both revenue and earnings.
Second-quarter revenue reached $15 billion, up 1% operationally and up 5% excluding COVID-19 products, exceeding the $14.4 billion consensus by 4.41%. Adjusted diluted EPS was $0.77, also beating expectations, representing a 13.24% beat over the $0.68 estimate. Growth was driven by an 18% operational increase in launched and acquired products, including continued demand for Eliquis, Padcev, the Vyndaqel family, and Lorbrena, which offset continued declines in COVID-19 product sales.
Pfizer raised its full-year 2026 revenue guidance to $60.5 billion to $62.5 billion, up from a prior range of $59.5 billion to $60.5 billion, and reaffirmed adjusted diluted EPS guidance of $2.80 to $3.00. CEO Albert Bourla highlighted continued progress in the company's obesity and oncology pipelines, while the company also disclosed a $4.3 billion non-cash intangible asset impairment charge for the quarter, which drove a GAAP net loss of $248 million.
Leadership Transition and Pipeline
Pfizer also announced a leadership transition, with Chief Financial Officer Dave Denton departing the company and Cecile Zhigang stepping in as interim CFO. The company reaffirmed confidence in returning to high single-digit revenue growth from 2029 onward, supported by a bottoms-up analysis of pipeline assets including 20 key potential new medicines and vaccines.
On the pipeline front, Padcev received FDA approval for expansion into muscle-invasive bladder cancer, showing a 35% reduction in risk of death versus standard of care. The company's obesity candidate danuglipron, in collaboration with Metsera, is targeting a first approval in 2028, with 10 Phase 3 studies planned. Sigvotatug vedotin, an antibody-drug conjugate, showed mixed results in second-line non-small cell lung cancer, missing overall survival in the intent-to-treat population but showing benefit in a one-prior-line subgroup, while tildrakizumab demonstrated head-to-head superiority over Dupixent in a Phase 3 trial.
On capital allocation, Pfizer returned $5.5 billion to shareholders via dividends and $4.9 billion in research and development investment in the first half of 2026, with business development capacity of approximately $6 billion post-Inventiv deal at a leverage ratio of 2.7 times. Management reaffirmed its commitment to maintaining and over time growing the dividend, expressing confidence in maintaining it even in stretched scenarios.
Pfizer's market capitalization stood at $144.82 billion, with a trailing price-to-earnings ratio of 8.30 and a dividend yield of 6.77%. The stock's 52-week range spans $23.58 to $28.75.
Conclusion
Pfizer's second-quarter beat and raised full-year guidance, alongside continued pipeline execution, appear to be supporting investor confidence even as the company navigates a CFO transition. With management projecting a return to high single-digit growth from 2029 and an expanding late-stage pipeline, the stock's near-term trajectory will likely hinge on continued execution against its raised guidance and further pipeline readouts.
This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...